CELF1 Knockout cell line (A549)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

CELF1 (CUGBP Elav-like family member 1) encodes an RNA-binding protein containing multiple RNA recognition motifs. The protein regulates pre-mRNA alternative splicing and contributes to mRNA editing and translation processes through interactions with target RNAs.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.